PMID- 37665078
OWN - NLM
STAT- MEDLINE
DCOM- 20231010
LR  - 20231010
IS  - 1756-185X (Electronic)
IS  - 1756-1841 (Linking)
VI  - 26
IP  - 10
DP  - 2023 Oct
TI  - Cost-effectiveness of alginic acid in combination with proton pump inhibitor for 
      the treatment of gastroesophageal reflux disease in systemic sclerosis patients.
PG  - 2037-2046
LID - 10.1111/1756-185X.14868 [doi]
AB  - BACKGROUND: Systemic sclerosis (SSc) patients often become refractory to proton 
      pump inhibitors (PPI)-a standard treatment for gastroesophageal reflux disease 
      (GERD)-and intolerant to PPI in combination with domperidone. PPI with alginic 
      acid is an alternative treatment option, but alginic acid is costly. OBJECTIVES: 
      We compared the costs and effectiveness of alginic acid plus PPI versus standard 
      treatments (PPI with/without antacids as needed and lifestyle modifications) for 
      GERD in SSc patients unsuitable for, or intolerant to, domperidone. METHODS: An 
      economic evaluation using the Markov model was conducted among SSc patients aged 
      between 40 and 65 years with GERD, having a partial or non-response to 4 weeks of 
      standard-dose omeprazole (40 mg/day) and being unsuitable for or intolerant to 
      domperidone. Using a societal perspective, we computed the incremental 
      cost-effectiveness ratios (ICERs) in terms of Thai baht (THB) per 
      quality-adjusted life-year (QALY) between a combination of alginic acid plus PPI 
      and standard treatment for GERD. The lifetime time horizon was used. RESULTS: The 
      ICER for alginic acid plus PPI versus standard treatments was 377 101 THB/QALY. 
      According to the one-way sensitivity analysis, the cost of alginic acid was the 
      most impactful parameter. If the market prices of alginic acid plus PPI were 
      reduced by 61%, this treatment option would become cost-effective at the 
      willingness-to-pay threshold of 160 000 THB/QALY (34.68 THB/USD data on 25 May 
      2023). Furthermore, if alginic acid were included in the public health insurance 
      program, the national budget would be increased by 66 313 THB per patient, 
      resulting in an overall budget increase of 5 106 101 to 8 885 942 THB compared 
      with the standard treatment. CONCLUSIONS: Alginic acid plus PPI does not 
      represent good value for money compared with the standard treatment among such 
      SSc patients in Thailand unless its price is reduced significantly.
CI  - (c) 2023 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons 
      Australia, Ltd.
FAU - Foocharoen, Chingching
AU  - Foocharoen C
AUID- ORCID: 0000-0002-1964-4389
AD  - Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
FAU - Kingkaew, Pritaporn
AU  - Kingkaew P
AD  - The Health Intervention and Technology Assessment Program (HITAP), Department of 
      Health, Ministry of Public Health, Nonthaburi, Thailand.
FAU - Teerawattananon, Yot
AU  - Teerawattananon Y
AD  - The Health Intervention and Technology Assessment Program (HITAP), Department of 
      Health, Ministry of Public Health, Nonthaburi, Thailand.
FAU - Mahakkanukrauh, Ajanee
AU  - Mahakkanukrauh A
AUID- ORCID: 0000-0002-7091-0259
AD  - Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
FAU - Suwannaroj, Siraphop
AU  - Suwannaroj S
AD  - Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
FAU - Manasirisuk, Witsarut
AU  - Manasirisuk W
AD  - Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
FAU - Chaiyarit, Jitjira
AU  - Chaiyarit J
AD  - Department of Statistics, Faculty of Science, Khon Kaen University, Khon Kaen, 
      Thailand.
FAU - Sangchan, Apichat
AU  - Sangchan A
AD  - Special Medical Center, Srinagarind Hospital, Faculty of Medicine, Khon Kaen 
      University, Khon Kaen, Thailand.
LA  - eng
GR  - the Research and Graduate Studies, Khon Kaen University, Thailand/
PT  - Journal Article
DEP - 20230904
PL  - England
TA  - Int J Rheum Dis
JT  - International journal of rheumatic diseases
JID - 101474930
RN  - 0 (Proton Pump Inhibitors)
RN  - 8C3Z4148WZ (Alginic Acid)
RN  - 5587267Z69 (Domperidone)
SB  - IM
MH  - Humans
MH  - Infant, Newborn
MH  - Proton Pump Inhibitors/adverse effects
MH  - Alginic Acid/therapeutic use
MH  - Cost-Benefit Analysis
MH  - Domperidone/therapeutic use
MH  - *Gastroesophageal Reflux/diagnosis/drug therapy
MH  - *Scleroderma, Systemic/complications/diagnosis/drug therapy
OTO - NOTNLM
OT  - alginic acid
OT  - cost-effectiveness
OT  - domperidone
OT  - economic
OT  - gastroesophageal reflux diseases
OT  - proton pump inhibitors
OT  - quality indicator and health care
OT  - quality of life
OT  - scleroderma and related disorders
OT  - systemic sclerosis
EDAT- 2023/09/04 12:42
MHDA- 2023/10/10 06:41
CRDT- 2023/09/04 07:13
PHST- 2023/07/28 00:00 [revised]
PHST- 2023/05/24 00:00 [received]
PHST- 2023/07/31 00:00 [accepted]
PHST- 2023/10/10 06:41 [medline]
PHST- 2023/09/04 12:42 [pubmed]
PHST- 2023/09/04 07:13 [entrez]
AID - 10.1111/1756-185X.14868 [doi]
PST - ppublish
SO  - Int J Rheum Dis. 2023 Oct;26(10):2037-2046. doi: 10.1111/1756-185X.14868. Epub 
      2023 Sep 4.